相关实验视频

Updated: May 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在EGFR突变阳性患者的预后因素患有肺腺癌的骨转移

Shunzo Osaka¹, Junzo Kawashima¹, Ryoma Kaguchi¹

¹Orthopaedic Surgery,Kasukabe Medical Center, Saitama, Japan.

Cancer diagnosis & prognosis

|May 5, 2025

概括

在EGFR突变阳性患者中分析了带有骨转移的肺腺癌的预后因素. 绩效状况和寡卵性转移状况显著影响了中位生存时间.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

在患有骨转移和EGFR突变的肺腺癌患者中研究了预后因素.
专注于117名患者的队列,详细分析了45例EGFR突变阳性病例.

研究的目的:

确定影响EGFR突变阳性肺腺癌与骨转移的生存的关键预后因素.
评估性能状况,寡度转移状况,放射治疗和EGFR-氨酸激酶抑制剂 (TKI) 给药对生存结果的影响.

主要方法:

对117名患有骨转移的肺腺癌患者的回顾性审查.
对45名EGFR突变阳性患者的分析,评估基于表现状态,寡度转移状态,放射治疗和TKI治疗的生存率.

主要成果:

阳性EGFR突变患者的5年生存率为9.2%,中位数生存时间为22.7个月.
平均存活时间根据表现状态 (PS) 和寡度转移状态显著不同.
骨放射治疗没有影响整体存活率,但缓解了疼痛并预防了.

结论:

性能状况和寡度转移状态是EGFR突变阳性肺腺癌与骨转移的关键预后因素.
顺序使用第一/第二代EGFR-TKIs,其次是第三代TKIs作为一线治疗,证明了有利的结果.
骨辐射疗法在这个患者群体中为疼痛和预防提供了缓解益处.

关键词:

在 EGFR 基因突变.肺癌是一种肺癌.腺癌瘤是一种腺癌.骨转移的发生.预后因素是一个预后因素.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...